These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 28039445

  • 1. Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo.
    Wright LE, Harhash AA, Kozlow WM, Waning DL, Regan JN, She Y, John SK, Murthy S, Niewolna M, Marks AR, Mohammad KS, Guise TA.
    Oncotarget; 2017 Jan 31; 8(5):8406-8419. PubMed ID: 28039445
    [Abstract] [Full Text] [Related]

  • 2. Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo.
    Ottewell PD, Wang N, Brown HK, Reeves KJ, Fowles CA, Croucher PI, Eaton CL, Holen I.
    Clin Cancer Res; 2014 Jun 01; 20(11):2922-32. PubMed ID: 24687923
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A single intravenous administration of zoledronic acid prevents the bone loss and mechanical compromise induced by aromatase inhibition in rats.
    Gasser JA, Green JR, Shen V, Ingold P, Rebmann A, Bhatnagar AS, Evans DB.
    Bone; 2006 Oct 01; 39(4):787-95. PubMed ID: 16844441
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.
    Zysk A, DeNichilo MO, Panagopoulos V, Zinonos I, Liapis V, Hay S, Ingman W, Ponomarev V, Atkins G, Findlay D, Zannettino A, Evdokiou A.
    Cancer Lett; 2017 Feb 01; 386():141-150. PubMed ID: 27865798
    [Abstract] [Full Text] [Related]

  • 7. The combined use of Camellia sinensis and metronomic zoledronic acid in a breast cancer-induced osteolysis mouse model.
    Luo KW, Ko CH, Yue GG, Gao S, Lee JK, Li G, Fung KP, Leung PC, Evdokiou A, Lau CB.
    J Cancer Res Clin Oncol; 2015 Jun 01; 141(6):1025-36. PubMed ID: 25431338
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Low-Magnitude Mechanical Signals Combined with Zoledronic Acid Reduce Musculoskeletal Weakness and Adiposity in Estrogen-Deprived Mice.
    Pagnotti GM, Trivedi T, Wright LE, John SK, Murthy S, Pattyn RR, Willis MS, She Y, Suresh S, Thompson WR, Rubin CT, Mohammad KS, Guise TA.
    bioRxiv; 2023 Mar 13. PubMed ID: 36993656
    [Abstract] [Full Text] [Related]

  • 12. Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease.
    Dedes PG, Kanakis I, Gialeli Ch, Theocharis AD, Tsegenidis T, Kletsas D, Tzanakakis GN, Karamanos NK.
    Biochim Biophys Acta; 2013 Jun 13; 1830(6):3625-34. PubMed ID: 23395844
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Aromatase and breast cancer.
    Brodie A, Sabnis G, Jelovac D.
    J Steroid Biochem Mol Biol; 2006 Dec 13; 102(1-5):97-102. PubMed ID: 17113978
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid.
    Misso G, Porru M, Stoppacciaro A, Castellano M, De Cicco F, Leonetti C, Santini D, Caraglia M.
    Cancer Biol Ther; 2012 Dec 13; 13(14):1491-500. PubMed ID: 22990205
    [Abstract] [Full Text] [Related]

  • 19. Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo.
    Ju YH, Doerge DR, Woodling KA, Hartman JA, Kwak J, Helferich WG.
    Carcinogenesis; 2008 Nov 13; 29(11):2162-8. PubMed ID: 18632754
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of a cathepsin K inhibitor in a preclinical model for prevention and treatment of breast cancer bone metastasis.
    Duong LT, Wesolowski GA, Leung P, Oballa R, Pickarski M.
    Mol Cancer Ther; 2014 Dec 13; 13(12):2898-909. PubMed ID: 25249554
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.